Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Clafix** is a Positif Life Sciences marketed oral fixed-dose antibacterial product containing **amoxicillin 500 mg plus clavulanic acid 125 mg** per film-coated tablet. Amoxicillin is a bactericidal aminopenicillin that inhibits bacterial cell-wall synthesis through penicillin-binding proteins, while clavulanic acid inhibits susceptible bacterial beta-lactamases and protects amoxicillin from enzymatic degradation. The product is used for susceptible bacterial infections, including respiratory, ear, urinary-tract, skin and soft-tissue, bone, joint, and dental infections. ([positifchd.in](https://www.positifchd.in/downloads/pricelist.xls))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on amoxicillin + clavulanic acid (Positif Life Sciences).